瑞博生物-首次覆盖给予买入评级-siRNA 药物开发领域的先驱，具备全球雄心

Suzhou Ribo Life Science is a leading player in siRNA with key strengths including: 1) leading and differentiated pipeline candidates, 2) leading drug delivery technology platforms including both hepatic and extra-hepatic delivery, and 3) global ambitions supported by collaboration with international pharma partners. We think the key candidate, FXI-targeting siRNA RBD4059, could be a breakthrough drug for treatment of thrombotic diseases with sales potential >$6bn, a potential we think is underestimated by ...